A new risk score can help predict which pancreatic cancer survivors are more likely to suffer a recurrence of their cancer, ...

A new risk score may identify patients with node-negative pancreatic neuroendocrine tumors who face a high risk for recurrence after surgery.

Known as the 21-gene recurrence score, the test is a personalized analysis of the activity of 21 genes found in a patient's breast tumor tissue. The score can be used to predict whether, after ...

Please provide your email address to receive an email when new articles are posted on . Oncotype DX Breast Recurrence Score appeared to be associated with mortality at a lower threshold for men with ...

A new study shows that a test physicians commonly used to guide chemotherapy treatment for post-breast cancer surgery patients may also help them decide whether radiation therapy may be of benefit.

MADISON, Wis., April 28, 2022 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a leader in advanced cancer diagnostics, today announced that recommended use of its Oncotype DX Breast Recurrence ...

Cedars-Sinai investigators, leading a multi-institutional team, have developed and validated a tool to predict which patients with pancreatic neuroendocrine tumors (PanNETs) need closer monitoring ...

In the prospective TAILORx trial, 93% of women with hormone-sensitive, HER2-negative, axillary node-negative breast cancer and a high Recurrence Score 26-100 were estimated to be cancer-free at five ...

Exact Sciences, a leading provider of cancer screening and diagnostic tests, today announced that the UK’s National Institute for Health and Care Excellence (NICE) has recommended the expanded use of ...